Edwards, Mark Gearard - 2019
Everyone knows that immune-oncology (IO) is the hottest ticket in biopharma alliances. With almost 100 announced deals involving PD-1, and more than half as many with PD-L1, it seems that everyone is jumping onto the IO dancefloor. However, as with all things alliance-related, the devil is in...